37 research outputs found
PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Get PDFPCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB
No full textPUK8 ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES
No full textDU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Get PDFCN1 RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING
No full textPCN98 IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS
No full textResource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities
No full textPND8 THE IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF G4 EUROPEAN COUNTRIES
No full textDU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
No full text
